Montelukast Gedeon Richter (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Gedeon Richter, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as prescribed and is approved in the European Union for long‑term management of airway inflammation.

GNH USA supplies Montelukast Gedeon Richter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to GMP standards and providing regulatory documentation for importers.

Montelukast Gedeon Richter is a leukotriene receptor antagonist used to manage respiratory and allergic conditions. - Asthma: improves control of symptoms and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis. - Mood changes, including depression or suicidal thoughts. - Severe skin reactions like Stevens‑Johnson syndrome. - Hepatic injury: rare liver enzyme elevations.

When prescribing Montelukast Gedeon Richter, clinicians should consider several safety precautions. - Assess liver function: monitor patients with hepatic disease. - Review psychiatric history: observe for mood alterations or suicidal ideation. - Check for hypersensitivity: avoid in individuals with known allergy to montelukast. - Use caution in renal impairment: dose adjustment may be required in severe cases. - Store at room temperature: keep in the original container, protect from moisture.

Montelukast can interact with other medicines, influencing its plasma levels or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibitor that can raise montelukast concentrations. - Phenobarbital, carbamazepine, phenytoin: strong CYP inducers that may lower montelukast exposure. - Fluconazole: moderate CYP3A4 inhibitor that can increase montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: concurrent use can increase theophylline side effects. - Beta‑agonists (e.g., albuterol): additive bronchodilation; monitor respiratory response.